Edition:
India

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

3.30USD
11:16pm IST
Change (% chg)

$-0.04 (-1.20%)
Prev Close
$3.34
Open
$3.33
Day's High
$3.39
Day's Low
$3.21
Volume
587,421
Avg. Vol
1,249,936
52-wk High
$18.50
52-wk Low
$3.21

Latest Key Developments (Source: Significant Developments)

Endo International - Unit Par Pharmaceutical Priced $1.5 Billion Of 7.500% Senior Secured Notes Due 2027 At $1,000 Per $1,000 Principal Amount
Friday, 15 Mar 2019 

March 14 (Reuters) - Endo International PLC ::ENDO INTERNATIONAL PLC ANNOUNCES PRICING OF PRIVATE OFFERING OF SENIOR SECURED NOTES.ENDO INTERNATIONAL - UNIT PAR PHARMACEUTICAL PRICED $1.5 BILLION OF 7.500% SENIOR SECURED NOTES DUE 2027 AT $1,000 PER $1,000 PRINCIPAL AMOUNT.  Full Article

Endo International PLC Announces Debt Refinancing Transactions
Thursday, 14 Mar 2019 

March 14 (Reuters) - Endo International PLC ::ENDO INTERNATIONAL PLC ANNOUNCES DEBT REFINANCING TRANSACTIONS, INCLUDING CASH TENDER OFFERS AND CONSENT SOLICITATIONS FOR UP TO $1.0 BILLION AGGREGATE PURCHASE PRICE OF ITS OUTSTANDING SENIOR NOTES.ENDO INTERNATIONAL PLC ANNOUNCES DEBT REFINANCING TRANSACTIONS, INCLUDING CASH TENDER OFFERS AND CONSENT SOLICITATIONS FOR UP TO $1.0 BILLION AGGREGATE PURCHASE PRICE OF ITS OUTSTANDING SENIOR NOTES.ENDO INTERNATIONAL PLC - EACH OF TENDER OFFERS AND CONSENT SOLICITATIONS WILL EXPIRE ON APRIL 10, 2019.  Full Article

Endo International PLC Announces Proposed Private Offering Of Senior Secured Notes
Thursday, 14 Mar 2019 

March 14 (Reuters) - Endo International PLC ::ENDO INTERNATIONAL PLC ANNOUNCES PROPOSED PRIVATE OFFERING OF SENIOR SECURED NOTES.ENDO INTERNATIONAL - INTENDS TO USE PROCEEDS FROM PROPOSED OFFERING TO PURCHASE A PORTION OF ENDO'S OUTSTANDING SENIOR UNSECURED NOTES, OTHERS.  Full Article

Perrigo Confirms Patent Challenge For Generic Version Of Nascobal
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Perrigo Company PLC ::PERRIGO CONFIRMS PATENT CHALLENGE FOR GENERIC VERSION OF NASCOBAL.PERRIGO COMPANY PLC - ENDO PHARMA INITIATED PATENT LITIGATION REGARDING PERRIGO'S PARAGRAPH IV ABBREVIATED NDP FOR CYANOCOBALAMIN NASAL SPRAY 500MCG.  Full Article

Endo Announces FDA Decision Not To Include Vasopressin On 503B Bulks List
Saturday, 2 Mar 2019 

March 1 (Reuters) - Endo International PLC ::ENDO ANNOUNCES FDA DECISION NOT TO INCLUDE VASOPRESSIN ON 503B BULKS LIST.ENDO - ANTICIPATE DISCUSSING WITH FDA IMPACT OF DECISION NOT TO INCLUDE VASOPRESSIN ON 503B BULKS LIST ON CO'S PENDING LITIGATION IN NEAR FUTURE.  Full Article

Endo Agrees Not To Oppose Additional Stay Of FDA Litigation Following Restoration Of Government Appropriations
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Endo International PLC ::ENDO AGREES NOT TO OPPOSE ADDITIONAL STAY OF FDA LITIGATION FOLLOWING RESTORATION OF GOVERNMENT APPROPRIATIONS.ENDO INTERNATIONAL - U.S. FDA HAS REQUESTED A FURTHER STAY OF ENDO'S ONGOING LITIGATION AGAINST FDA THROUGH MARCH 15, 2019.  Full Article

Endo Agrees Not To Oppose Additional Stay Of FDA Litigation Following Restoration Of Govt Appropriations
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Endo International PLC ::ENDO AGREES NOT TO OPPOSE ADDITIONAL STAY OF FDA LITIGATION FOLLOWING RESTORATION OF GOVERNMENT APPROPRIATIONS.ENDO INTERNATIONAL PLC - FDA REQUESTED A FURTHER STAY OF ENDO'S ONGOING LITIGATION AGAINST FDA THROUGH MARCH 15, 2019.ENDO INTERNATIONAL - IN STAY MOTION FDA "EXPECTS TO PUBLISH FINAL CLINICAL NEED DETERMINATION FOR VASOPRESSIN ON OR BEFORE MARCH 15, 2019.".  Full Article

Endo Anticipates Further Stay Of Compounding Litigation Due To Lapse Of Govt Appropriations
Monday, 31 Dec 2018 

Dec 31 (Reuters) - Endo International PLC ::ENDO ANNOUNCES ANTICIPATED FURTHER STAY OF COMPOUNDING LITIGATION DUE TO LAPSE OF GOVERNMENT APPROPRIATIONS.ENDO INTERNATIONAL PLC - FDA FILED A MOTION, SEEKING A FURTHER STAY OF SUIT FOR PERIOD OF TIME IN WHICH GOVERNMENT LACKS APPROPRIATIONS.ENDO INTERNATIONAL PLC - ENDO, OTHER INTERESTED PARTIES HAVE SUBMITTED COMMENTS ON FDA'S PROPOSED VASOPRESSIN DETERMINATION.ENDO INTERNATIONAL - IN LIGHT OF APPROPRIATIONS LAPSE, PROPOSED VASOPRESSIN DETERMINATION WILL NOW NOT OCCUR BY DEC 31, 2018.ENDO INTERNATIONAL PLC - IF FDA'S MOTION IS GRANTED, LITIGATION WILL BE STAYED FOR AS LONG AS APPROPRIATIONS LAPSE CONTINUES.ENDO INTERNATIONAL PLC - IS NOT AT THIS TIME AWARE WHEN APPROPRIATIONS MAY RESUME.  Full Article

Catalyst Pharmaceuticals Announces Definitive Agreement With Endo For Vigabatrin Tablets
Tuesday, 18 Dec 2018 

Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS ANNOUNCES DEFINITIVE AGREEMENT WITH ENDO FOR VIGABATRIN TABLETS.CATALYST PHARMACEUTICALS INC - WILL RECEIVE AN UP-FRONT PAYMENT, MILESTONE PAYMENTS BASED ON ACHIEVEMENT OF REGULATORY APPROVALS.CATALYST PHARMACEUTICALS INC - UNDER DEAL, CO TO ALSO RECEIVE SHARING OF DEFINED NET PROFITS UPON COMMERCIALIZATION.CATALYST PHARMACEUTICALS - SIGNED AGREEMENT WITH ENDO INTERNATIONAL'S UNIT FOR FURTHER DEVELOPMENT,COMMERCIALIZATION OF GENERIC SABRIL TABLETS.  Full Article

Endo International Says Timing Of Launch For Cellulite Treatment CCH Will Be Second Half Of 2020
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Endo International PLC ::SAYS EXPECTS TO SUBMIT MARKETING APPLICATION FOR CELLULITE TREATMENT CCH IN SECOND HALF OF 2019 - CONF. CALL.SAYS TIMING OF LAUNCH FOR CELLULITE TREATMENT CCH WILL BE SECOND HALF OF 2020- CONF. CALL.  Full Article

Endo gains on favorable FDA drug compounding decision

Endo International Plc said on Friday the U.S. health regulator has decided https://bit.ly/2XGrm1k not to include blood pressure treatment vasopressin in its list of drugs that can be used in compounding, in a boost to the drugmaker that makes the only FDA-approved version of the product.